(Q46013515)

English

Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.

scientific article published on 14 May 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

0 references

0 references

1 reference

based on heuristic

inferred from title

Krzysztof Giannopoulos

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Ewa Wasik-Szczepanek

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Agnieszka Bojarska-Junak

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Jacek Roliński

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Jacek Roliński

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Anna Dmoszyńska

2

object named as

A Dmoszynska

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

M Kowal

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

H Döhner

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

S Stilgenbauer

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

L Bullinger

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

14 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1771-1778

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Role of angiogenesis in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Immunomodulating drugs for chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

MYC stimulates EZH2 expression by repression of its negative regulator miR-26a

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Lenalidomide for the treatment of B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Phosphorylation controls Ikaros's ability to negatively regulate the G(1)-S transition

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Clinical translation of gene expression profiling in lymphomas and leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by 4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

21 January 2018

Biology and treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

7 January 2021

based on heuristic

inferred from DOI database lookup

New prognostic markers in CLL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

7 January 2021

based on heuristic

inferred from DOI database lookup

The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.98

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2009.98

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19440214%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46013515&oldid=2207528803"